Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

781421

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Illnesses: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on the medicine-taking behaviour of patients who rely on regular and multiple medications to prevent symptoms of long-term conditions.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110622
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110620 110621 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781420

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Illnesses: Pre-payment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on patients with a long-term condition who have already purchased a prescription prepayment certificate.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110621
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110620 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781417

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Illnesses: Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on patients with (a) inflammatory bowel disease and (b) a long-term condition.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110618
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110619 110620 110621 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781419

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments: Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on access to medications for (a) children, (b) older people and (c) other vulnerable people.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110620
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110621 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781418

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on (a) the management of urgent care services and (b) the number of hospital admissions.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110619
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110620 110621 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

760701

	registered interest
	date	14/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dental Services: Contracts
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the total value of undelivered contracted units of dental activity in NNS dental contracts in England was in each year from 2012 to 2017.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	105147
	answer	answer is ministerial correction date of answer 09/10/2017 answer text <p>The table below shows:</p><p>- the contracted units of dental activity not delivered through National Health Service dental contracts;</p><p>- total value of under delivered contracted units of dental activity; and</p><p>- number of contracts where not all contracted units of dental activity were delivered in England, for each year from 2012/13- 2016/17.</p><table><tbody><tr><td><p> </p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td></tr><tr><td><p>Contracted units of dental activity not delivered through NHS dental contracts in England (to 100% level)</p></td><td><p>5,210,585</p></td><td><p>3,812,758</p></td><td><p>3,799,633</p></td><td><p>4,352,738</p></td><td><p>4,363,613</p></td></tr><tr><td><p>Total value of under delivered contracted units of dental activity in NHS dental contracts in England (to 100% level) (£)</p></td><td><p>113,854,578</p></td><td><p>95,227,354</p></td><td><p>105,711,840</p></td><td><p>120,090,256</p></td><td><p>128,842,469</p></td></tr><tr><td><p>NHS dental contracts in England where not all contracted units of dental activity delivered in each year (to 100% level)</p></td><td><p>3,320</p></td><td><p>2,659</p></td><td><p>2,704</p></td><td><p>2,688</p></td><td><p>2,409</p></td></tr></tbody></table><p> </p><p><br /></p><p>Notes:</p><p>- The table includes contracts closed during the year.</p><p>- Contracted units of dental activity not delivered through NHS dental contracts does not assume that up to 4% of under delivery is carried forward by the contractor, for delivery in the subsequent year (up to 4% under delivery is a contractual tolerance managed by commissioners).</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/10/2017 16:32:06 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

784947

	registered interest
	date	06/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to improve patient access to preventative drugs for breast cancer.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	111559
	answer	answer is ministerial correction date of answer 17/11/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently updating its guideline on the diagnosis and management of early and locally advanced breast cancer. The use of adjuvant bisphosphonates has been identified as one of the key areas that will be covered in the update which is scheduled for publication in July 2018. In the meantime, NICE has published an evidence summary on the use of adjuvant bisphosphonates in early breast cancer. NHS England expects clinical commissioning groups to take account of NICE guidelines and local population needs when making commissioning decisions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/11/2017 11:39:23 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

784923

	registered interest
	date	06/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medicine: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment he has made of the (a) affordability and (b) accessibility of medicines which are produced through publicly-funded medical research.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	111610
	answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>We have made no assessment. The National Institute for Health and Care Excellence (NICE) assesses medicines on the basis of their value to patients and to the National Health Service. The source of financial support in developing each medicine is not assessed.</p><p> </p><p>The NHS is required by law to ensure that all medicines recommended by NICE are funded within three months, ensuring patient access to cost-effective medicines in England. New medicines are not subject to payments under the voluntary Pharmaceutical Price Regulation Scheme, and NHS England monitors access to innovative medicines via the Innovation Scorecard in recognition of the value this Government places on innovation.</p><p> </p><p>Many countries fund research and development (R&amp;D), often at an early stage. Private companies also invest in R&amp;D. It is not possible to assess the contribution made by public investment or private investment in bringing products to market.</p><p> </p><p>The Government and its partners recently published the response to the Accelerated Access Review which sets out plans to give patients quicker access to life-changing treatments and make the United Kingdom the best place in the world for industry to invest and innovate. A total of £86 million of funding has already been committed to make the vision a reality.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/11/2017 16:48:27 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

784942

	registered interest
	date	06/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what progress he has made on the implementation of the Cancer Strategy; and what resources from the public purse he has allocated for that implementation.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	111561
	answer	answer is ministerial correction date of answer 14/11/2017 answer text <p>NHS England has confirmed funding of £607 million between 2017/18 and 2020/21 to support delivery of the Cancer Strategy for England. Progress on implementation and the full investment in delivering the strategy is set out in the Progress Report for 2016/17 published in October 2017 at:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/11/2017 12:09:56 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

784943

	registered interest
	date	06/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans =he-she has to reform the process for (a) appraisal and (b) funding of life-extending medicines for cancer patients.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	111560
	answer	answer is ministerial correction date of answer 17/11/2017 answer text <p>Following a public consultation, NHS England and the National Institute for Health and Care Excellence introduced new arrangements for the appraisal and funding of cancer drugs in July 2016. The new arrangements, including the Cancer Drugs Fund, are designed to ensure that patients benefit from faster access to the most promising new drugs whilst delivering better value for money for the taxpayer.</p><p> </p><p>On 3 November, the Government published its response to the Accelerated Access Review. It set out plans to give patients quicker access to life-changing treatments and make the United Kingdom the best place in the world for industry to invest and innovate. From April 2018, the new Accelerated Access Pathway will mean selected products with the greatest potential to change lives could be available up to four years earlier by reducing the time taken to negotiate the evaluation and financial approvals necessary before the National Health Service can purchase them.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/11/2017 11:41:32 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe